title: Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults.
abstract: BACKGROUND
  A growing body of evidence has linked vitamin D deficiency to increased risk of cardiovascular disease. Vitamin D deficiency is also more common in African Americans for whom an increased cardiovascular disease risk exists. This study sought to test the hypothesis that 16 weeks of 60,000 IU monthly supplementation of oral vitamin D(3) would improve flow-mediated dilation (FMD) in African Americans, whereas no change would be observed in the placebo group.
  
  
  METHODS
  A randomized, double-blind, placebo-controlled clinical trial was conducted. Fifty-seven African-American adults were randomly assigned to either the placebo group or vitamin D group.
  
  
  RESULTS
  Following 16 weeks of placebo (n = 23; mean age 31 ± 2 years) or 60,000 IU monthly oral vitamin D(3) (n = 22; mean age 29 ± 2 years), serum concentrations of 25-hydroxyvitamin D (25(OH)D) increased from 38.2 ± 3.0 to 48.7 ± 3.2 nmol/l and 34.3 ± 2.2 to 100.9 ± 6.6 nmol/l, respectively. No changes in serum parathyroid hormone (PTH), serum calcium, or urine calcium/creatinine were observed following either treatment. Following 16 weeks of treatment, significant improvements in FMD were only observed in the vitamin D group (1.8 ± 1.3%), whereas the placebo group had no change (-1.3 ± 0.6%). Similarly, the vitamin D group exhibited an increase in absolute change in diameter (0.005 ± 0.004 cm) and FMD/shear (0.08 ± 0.04 %/s(-1), area under the curve (AUC) × 10(3)) following treatment, whereas no change (-0.005 ± 0.002 cm and -0.02 ± 0.02 %/s(-1), AUC, respectively) was observed following placebo.
  
  
  CONCLUSIONS
  Supplementation of 60,000 IU monthly oral vitamin D(3) (~2,000 IU/day) for 16 weeks is effective at improving vascular endothelial function in African-American adults.
authors.affiliation: Georgia Prevention Institute, Department of Pediatrics, Medical College of Georgia, Augusta, USA.
authors.forename: Ryan A
authors.initials: RA
authors.lastname: Harris
authors.forename: Jennifer
authors.initials: J
authors.lastname: Pedersen-White
authors.forename: De-Huang
authors.initials: DH
authors.lastname: Guo
authors.forename: Inger S
authors.initials: IS
authors.lastname: Stallmann-Jorgensen
authors.forename: Daniel
authors.initials: D
authors.lastname: Keeton
authors.forename: Ying
authors.initials: Y
authors.lastname: Huang
authors.forename: Yashesh
authors.initials: Y
authors.lastname: Shah
authors.forename: Haidong
authors.initials: H
authors.lastname: Zhu
authors.forename: Yanbin
authors.initials: Y
authors.lastname: Dong
mesh_terms: D000328:Adult; D001741:Black or African American; D002762:Cholecalciferol / Q000008:administration & dosage; D019587:Dietary Supplements; D004311:Double-Blind Method; D004730:Endothelium, Vascular / Q000502:physiology*; D005260:Female; D006801:Humans; D008297:Male; D050177:Overweight / Q000503:physiopathology*; D014664:Vasodilation; D014807:Vitamin D / Q000031:analogs & derivatives / Q000097:blood; D014808:Vitamin D Deficiency / Q000503:physiopathology
chemical_list: D014807:Vitamin D; D002762:Cholecalciferol; C104450:25-hydroxyvitamin D